Research Article Details
| Article ID: | A27306 |
| PMID: | 18683746 |
| Source: | Zhonghua Fu Chan Ke Za Zhi |
| Title: | [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study]. |
| Abstract: | OBJECTIVE: To explore the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with polycystic ovary syndrome (PCOS). METHODS: A case-control study employing 60 nonpregnant patients with PCOS and 60 non-pregnant patients without PCOS as control was conducted to compare the prevalence of NAFLD. RESULTS: The aminotransferase (ALT), fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) levels were (29 +/- 15) U/L, (19 +/- 12) mU/L and 0.47 +/- 0.29 in PCOS group, which were significantly higher (P < 0.05) than corresponding parameters in control group [(15 +/- 13) U/L, (11 +/- 8) mU/L and 0.31 +/- 0.21)]. The occurrence of insulin resistance and NAFLD was63% (38/60) and 42% (25/60), higher than those in control group [35% (21/60) and 20% (12/60), P < 0.05]. The increment of ALT was 40% (24/60) in PCOS group, higher than that of 3% (2/60) in control group (P < 0.01). Compared with patients without NAFLD, patients with NAFLD had significantly increased body mass index (P < 0.01), waist-hip ratio, ALT, C-reaction protein, fasting insulin, insulin and HOMA-IR levels 2 hours after oral glucose tolerance test (P < 0. 05). CONCLUSION: The increased prevalence of NAFLD in PCOS patients suggests an association between these two conditions and the necessity of hepatic screening among PCOS patients for potential NAFLD. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |